Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581419 | 0.92 | TSHR (0.38) | TSHRPDE10ARECQLALDH1A1HTT | |
| SCHEMBL1581447 | 0.91 | TSHR (0.41) | TSHRPDE10ARECQLALDH1A1HTT | |
| SCHEMBL1581549 | 0.91 | TSHR (0.36) | TSHRPDE10ARECQLALDH1A1HTT | |
| SCHEMBL12340534 | 0.90 | TSHR (0.48) | TSHRPDE10ARECQLALDH1A1HTT | |
| SCHEMBL1581487 | 0.89 | TSHR (0.38) | TSHRPDE10ARECQLALDH1A1HTT | |
| SCHEMBL1581540 | 0.88 | TSHR (0.37) | TSHRPDE10ARECQLALDH1A1HTT | |
| SCHEMBL3990602 | 0.88 | TSHR (0.41) | TSHRPDE10ARECQLALDH1A1HTT | |
| SCHEMBL3987690 | 0.88 | TSHR (0.39) | TSHRPDE10ARECQLALDH1A1HTT | |
| Filibuvir SCHEMBL1053035 | 0.88 | TSHR (0.38) | TSHRPDE10ARECQLALDH1A1HTT | |
| Filibuvir SCHEMBL12748294 | 0.88 | TSHR (0.38) | TSHRPDE10ARECQLALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | TSHR 4713/4885PDE2A 2157/4885PDE10A 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.